News Article IMMUNE industrial Liviu Tudor Romania
by Property Forum | Industrial

FUTURE Designs, the UK-based designer and manufacturer of high-quality luminaires and bespoke lighting solutions, obtain the first IMMUNE Building Standard™ certification in the world for an industrial building, awarded by the Healthy by Design Building Institute (HDBI).

The new certification is a global open-source standard pioneered in April 2020 by Liviu Tudor, president of the European Property Federation and founder of Genesis Property. The standard is adaptable to any built environment, including industrial buildings, increasing the resilience of indoor spaces against current and future health threats and building trust among occupants.

“We are pleased to announce the world’s first IMMUNE™ factory standing as proof for the flexibility and versatility of this truly global standard. In the current economy, still facing the consequences of the Covid-19 pandemic, there are companies like FUTURE Designs that are laying out a coherent path to recovery, while demonstrating a ground-breaking approach and great leadership in protecting people’s health and wellbeing”, said Liviu Tudor, founder of Genesis Property and president of the European Property Federation.

“We have spent hundreds of hours and great resource investigating the most effective and efficient means to ensure our premises are sanitized to bat away the coronavirus. Our sole goal was to make our place of work the safest possible for all team members and to give them confidence and peace of mind during these extraordinary times”, says David Clements, Chief Executive at FUTURE Designs.

The IMMUNE™ standard is inspired by technologies and procedures developed and successfully applied in hospitals and medical clinics. Specifically, the standard is based on an IMMUNE™ Assessment Scoring Index comprising 120+ measures recommended for implementation in buildings that include technical solutions for architectural engineering, technology, and design, as well as operational protocols applied permanently or ready to activate in specific risk scenarios.